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Abstract
Background: Chikungunya virus (CHIKV) caused a major two-wave seventeen-month-long outbreak in
La Réunion Island in 2005–2006. The aim of this study was to refine clinical estimates provided by a
regional surveillance-system using a two-stage serological assessment as gold standard.
Methods: Two serosurveys were implemented: first, a rapid survey using stored sera of pregnant women,
in order to assess the attack rate at the epidemic upsurge (s1, February 2006; n = 888); second, a
population-based survey among a random sample of the community, to assess the herd immunity in the
post-epidemic era (s2, October 2006; n = 2442). Sera were screened for anti-CHIKV specific antibodies
(IgM and IgG in s1, IgG only in s2) using enzyme-linked immunosorbent assays. Seroprevalence rates were
compared to clinical estimates of attack rates.
Results: In s1, 18.2% of the pregnant women were tested positive for CHIKV specific antibodies (13.8%
for both IgM and IgG, 4.3% for IgM, 0.1% for IgG only) which provided a congruent estimate with the 16.5%
attack rate calculated from the surveillance-system. In s2, the seroprevalence in community was estimated
to 38.2% (95% CI, 35.9 to 40.6%). Extrapolations of seroprevalence rates led to estimate, at 143,000 and
at 300,000 (95% CI, 283,000 to 320,000), the number of people infected in s1 and in s2, respectively. In
comparison, the surveillance-system estimated at 130,000 and 266,000 the number of people infected for
the same periods.
Conclusion: A rapid serosurvey in pregnant women can be helpful to assess the attack rate when large
seroprevalence studies cannot be done. On the other hand, a population-based serosurvey is useful to
refine the estimate when clinical diagnosis underestimates it. Our findings give valuable insights to assess
the herd immunity along the course of epidemics.
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Chikungunya fever is an arbovirosis caused by Chikun-
gunya virus (CHIKV), a mosquito-transmitted alphavirus
belonging to the Togaviridae family [1,2]. CHIKV was first
isolated in 1952, during a Tanzanian outbreak [3]. It cir-
culated in Africa and Asia, where periodic outbreaks were
described in the past 50 years. In some areas, attack rates
had reached 80 to 90% [1,2]. Between February 2005 and
August 2006, a large Chikungunya fever outbreak swept
the Indian Ocean islands [4,5], including La Réunion
Island since April 2005, an overseas French department of
787,836 inhabitants (Figure 1). The mosquito specie
involved in La Réunion outbreak was Aedes (A.) albopictus
[6]. Most CHIKV infections were symptomatic [7] and
characterized by a dengue-like illness of sudden onset
combining high fever, poly-arthralgia, myalgia, headache,
asthenia and rash [8,9].
In La Réunion, the epidemic pattern was monitored
through a regional surveillance-system managed by the
Map of La Réunion IslandFigure 1
Map of La Réunion Island. The territory is divided into four regions: north bounded by orange and red lines, west bounded 
by orange, light green, dark green and red lines, south bounded by dark green and red lines, east by red lines. For each munic-
ipality, the ratio of laboratories which participated to the survey on pregnant woman and the related amount of the sera col-
lected (n = x) are listed in parentheses.Page 2 of 9
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"suspected cases", defined as subjects with a sudden fever
(T > 38.5°C) and incapacitating arthralgia [10,11]. This
surveillance-system relied on self-reports, emergency
stays, physician declarations, biology laboratories activity,
and active case-finding around the cases reported by a sen-
tinel physician network [11]. At the beginning of the out-
break it consisted in an active and retrospective case
detection around the cases declared, and then, when the
incidence sharply increased (by December 2005), in an
estimation of the cases obtained from reports of a sentinel
network [12].
Before the explosion of the epidemic in mid-January
2006, a herald wave occurred during the previous rainy
season; between March and July 2005, and led the CIRE to
record about 3,000 suspected cases of Chikungunya [13].
Later on and until December 2005, low case rates were
recorded without interruption. An exponential increase of
the cases reported was observed in late December 2005,
and January 2006 with a peak in February 2006 [11] (Fig-
ure 2). On February 15th 2006, the CIRE estimated
157,000 suspected cases of Chikungunya, i.e. a prevalence
rate of 20.3%. On July 5th 2006, the CIRE estimated the
burden more than 266,000, i.e. a prevalence rate of 34.3%
[14].
Number of weekly incident cases of Chikungunya, La Réunion Island, March 28th, 2005 – April 16th, 2006 (n = 244,000)Figur  2
Number of weekly incident cases of Chikungunya, La Réunion Island, March 28th, 2005 – April 16th, 2006 (n = 
244,000). Reported by the active case-finding system between weeks 9 and 50, 2005 or estimated from the sentinel physician 
network between week 51 of 2005 and week 15, 2006. Published by Renault P, et al. in Am J Trop Med Hyg, 2007, 77: 727–731 
[11], and reprinted with the kind permission of the American Society of Tropical Medicine and Hygiene (Atlanta, USA). "Survey 
1" corresponds to the rapid serological survey on pregnant women (January 15th 2006 to February 15th 2006); "Survey 2" cor-
responds to the population-based SEROCHIK survey (August 17th to October 20th 2006).Page 3 of 9
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attack rates provided by the surveillance-system for the
population of La Réunion Island at two critical times of
the 2005–2006 outbreak. That is why we conducted two
serosurveys, the first using stored sera of pregnant women
during the epidemic upsurge aimed at assessing the extent
of the outbreak, the second using a random sample of the
population aimed at giving a precise idea of the herd
immunity in the post-epidemic era.
Methods
Rapid survey on pregnant women, epidemic phase
We gathered sera of pregnant women yet available in out-
patient laboratories from a mandatory monthly serologi-
cal screening for congenital toxoplasmosis. The sera,
collected between January 15th and February 15th 2006,
were neither directly nor indirectly nominative, and could
only be identified by a unique code number. All of the 46
biological labs of La Réunion Island were invited to par-
ticipate to the survey. Out of these, the 28 participating
ones served the entire territory (Figure 1). However, only
19 labs provided valid sera which led to a non-represent-
ative amount of 888 valid sera, taken out of the 3888 sera
collected during the study period (389 in the north, 305
in the south, 174 in the west, 20 in the east). For this
study, designed to inform without delay public health
authorities on the extent of the outbreak, a selection bias
related to the absence of randomisation of labs was toler-
ated. Nevertheless, as daily routine sampling of pregnant
women was not dedicated to a precise laboratory, it is rea-
sonable to think that the repartition bias was not signifi-
cant. Statistical analysis was performed using SAS software
version 8 (SAS Institute, Cary, NC).
Population-based survey, post-epidemic phase
A cross-sectional study, the SEROCHIK survey, was con-
ducted between August 17th and October 20th 2006 from
a random sample of the community of Reunion Island
[7]. At the first sampling stage, the French National Insti-
tute for Statistics and Economical Studies (INSEE) ran-
domly selected 3032 households after stratification on
age, gender, the geographical area, municipality size, and
type of habitat. The geographical area of habitat was
defined according to the regional administrative bound-
ary into four micro-regions (Figure 1). The municipality
size was divided in ≤ or > 10,000 inhabitants. The type of
habitat was categorized into individual or collective hous-
ing (multifamily ≤ 20 or > 20 housings). At the second
stage, a Kish method was used to randomly choose one
person for each selected household [13].
Of the 3032 households randomly selected by INSEE, the
sampling plan led to a set of 2442 eligible subjects (after
exclusion of absents, persons with invalid address or who
refused to participate) which was recovered by INSEE on
age, gender, geographical area, and type of habitat.
The study was approved by the ethical committee for stud-
ies with human subjects (CPP) of Bordeaux and the
National Commission for Informatics and Liberty
(CNIL). All participants provided their informed consent
to answer the questionnaire and for collection of blood
on filter paper.
Statistical analysis was done by accounting for the sam-
pling design, and was performed using Stata software
(College Station, Texas). The population-based seropreva-
lence was compared to CIRE clinical estimates using a Chi
square test. A P-value < 0.05 was considered significant.
The population size used for the calculation of incidence
was 787,836 inhabitants (INSEE, April 2006).
Detection of chikungunya infections
For the rapid survey in pregnant women, 100 microliters
of stored sera already available in outpatient laboratories
were used. In the SEROCHIK survey, for each person con-
senting to a fingertip prick, a drop of blood was deposited
onto Whatman no.1 filter paper [15]. For both studies,
anti-CHIKV specific antibodies were screened using the
same enzyme-linked immunosorbent assay (ELISA) and a
CHIKV antigen produced by the Centre National de
Référence pour les Arbovirus (CNR, Lyon, France) [15].
For the rapid survey, the ELISA was performed at the CNR
whereas for the SEROCHIK survey, it was done using the
Groupe Hospitalier Sud – Réunion (GHSR) laboratory
facilities. Both IgM and IgG anti-CHIKV specific antibod-
ies were screened in sera from pregnant women, whereas
only IgG anti-CHIKV specific antibodies were screened in
the community. In parallel with the SEROCHIK survey,
the ability of the prick-method to discriminate the sero-
logical status was validated in an independent sample
(Fianu et al, unpublished data).
Results
The Chikungunya serological status (positive/negative)
stratified for each study is given in Table 1.
Survey on pregnant women, epidemic phase
During the studied period (epidemic phase, Figure 2), 162
pregnant women (out of 888 enrolled, i.e. 18.2%) tested
positive for antibodies to CHIKV (IgM and/or IgG). There
was serological evidence for a recent Chikungunya infec-
tion, as 123 subjects (13.8%) showed both IgM and IgG,
and 38 (4.3%) had IgM in the absence of IgG. Isolated
positive IgG were detected in only one case (0.1%).
Application of the Chikungunya prevalence obtained
from the pregnant women group to the community
resulted in a rough estimate of 143,386 (787,836 × 0.182)Page 4 of 9
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(Figure 3).
Population-based survey, post-epidemic phase
The seroprevalence result in the sample questioned is pre-
sented in Table 2. The overall seroprevalence for the com-
munity after recovery by the sampling plan weight (data
not shown) was estimated at 38.2% (95% CI, 35.9 to
40.6%), i.e., about 300,000 people infected (95% CI,
283,000 to 320,000) which was significantly different
that the 34.3% of people infected reported by CIRE (Chi
square test: 16.4, P < 0.001). The rate of inapparent cases
Table 1: Chikungunya serological status during the epidemic upsurge phase (rapid survey) and the post-epidemic era (population-
based survey), Reunion Island outbreak, 2005 – 2006.
Study Negative serology Positive serology Total
Pregnant women (rapid survey) 726 (81.8) 162 (18.2) † 888
Population (population – based survey) 1475 (60.4) 967 (39.6) ‡ 2442
Data are numbers of persons questioned and (row) percentages.
† IgM and IgG anti-ChikV specific antibodies tested.
‡ IgG anti-ChikV specific antibodies tested.
Comparison of monthly suspected, self-reported and confirmed cases of Chikungunya in La Réunion Island between April 2005 and October 2006Figure 3
Comparison of monthly suspected, self-reported and confirmed cases of Chikungunya in La Réunion Island 
between April 2005 and October 2006. The number of suspected cases recorded weekly by the CIRE (left scale) is com-
pared to the number of cases identified in the population-based SEROCHIK survey (right scale). For the serosurvey, both self-
reports (all subjects who have declared that they have been infected, without taking into account serology results) and con-
firmed self-reports (with a positive serology) are noted. We refer to the date of first clinical signs declared by the subjects dur-
ing the survey conducted between August 17th 2006 and October 20th 2006. "Suspected cases" are defined as cases with a 
sudden onset of fever with temperature > 38.5°C and incapacitating arthralgia.Page 5 of 9
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aware of their infection but were tested serologically pos-
itive to CHIKV) was calculated to be 5.0% (95% CI 3.9 –
6.2%), and the rate of false positive (i.e., subjects who
declared that they were infected but had negative serology
to CHIKV) was estimated to be 4.5%% (95% CI 3.7 –
5.6%). Out of the 967 serologically positive persons, 162
(16.7%) reported no symptoms.
As the CIRE only considered suspected cases, i.e. subjects
with fever above 38.5°C with incapacitating arthralgia, we
also took into account the symptoms reported in the
questionnaire of the SEROCHIK population-based sur-
vey.
The ten most frequent symptoms self-reported by the sub-
jects who declared a Chikungunya are presented with
their positive predictive value (PPV) in order of decreasing
frequency in Table 3. People who declared a Chikungunya
with sudden fever and incapacitating arthralgia repre-
sented 88.5% of all people who declared the disease and
87.0% of all positive serology (sensitivity and PPV for
both signs: 88.5% and 87.0%, respectively).
Discussion
In the current paper, we demonstrate the usefulness of
two different epidemiological methods to assess the bur-
den of a Chikungunya outbreak at two critical times of its
evolution.
The rapid seroprevalence survey conducted at the peak of
La Réunion Island epidemic on sera from pregnant
women provided an 18.2% seroprevalence rate (or a
rough estimate of 143,000 people infected) by February
15th, 2006. This result was obtained at a very low cost, at
a time when the attack rate of the infection in the popula-
tion and the herd immunity were unknown. Since 99% of
the 162 tested sera harbored IgM anti-CHIKV antibodies
and only one IgG anti-CHIKV antibodies only, it excluded
a previous (recent) significant circulation of the virus in
the island and thus suggested that the outbreak emerged
into a naïve population. This result is in agreement with
the 20% prevalence rate calculated for all parturient
Table 2: Chikungunya clinical status × serological status in the community.
Population-based survey, Reunion Island outbreak, August – October 2006 (post-epidemic era)
Chikungunya declared Negative serology Positive serology Total
"No" [82.5] 1217 [12.0] 116 [54.5] 1333
(91.3) (8.7) (100)
Yes" [8.0] 118 [83.2] 805 [37.9] 923
(12.8) (87.2) (100)
"I don't know" [9.5] 140 [4.8] 46 [7.6] 186
(75.3) (24.7) (100)
Total [100] 1475 [100] 967 [100] 2442
(60.4) (39.6) (100)
Data are numbers of persons questioned and (row) or [column] percentages.
Table 3: Chikungunya self-reported symptoms × serological status in the community.
Population-based survey, Reunion Island outbreak, August – October 2006 (post-epidemic era)
Symptoms Negative serology Positive serology * Total
Arthralgia 111 (12.6) 770 (87.4) 881
Fever 92 (10.9) 753 (89.1) 845
Asthenia 89 (12.8) 605 (87.2) 694
Headache 69 (11.2) 545 (88.8) 614
Myalgia 68 (12.0) 497 (88.0) 565
Rash 41 (7.7) 493 (92.3) 534
Pruritus 36 (7.9) 421 (92.1) 457
Vomiting 31 (14.2) 188 (85.8) 219
Diarrhea 21 (13.5) 135 (86.5) 156
Depression 19 (13.2) 125 (86.8) 144
Fever and arthralgia 89 (13.0) 594 (87.0) 683
Total 118 (100) 805 (100) 923
Data are numbers of persons questioned and (row) percentages. Positive Predictive value (PPV) *Page 6 of 9
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2006 [16], and with the magnitude of 26% reported in
pregnant women by April 2006 in Mayotte [17].
The rough estimate by the rapid serosurvey in pregnant
women is slightly higher but of the same magnitude than
the 130,000 cumulative number of suspected cases
deducted from the CIRE at the same time (attack rate of
16.5%) [18,19]. It is therefore noteworthy that the rate
observed in a targeted population of pregnant woman
gives a valuable insight upon the magnitude of the attack
rate in the community, and beyond, of the herd immu-
nity. This congruent result with the CIRE data suggests
that in February 2006 pregnant women yet behaved like
everyone and that their level of exposure to CHIKV was
not different to that observed for anybody else. In other
words, the message aimed at crystallising the pregnant
woman as vulnerable person to the threat of Chikun-
gunya [20] and the measures aimed at reducing her expo-
sure [21], e.g., wear of long clothing, free distribution of
insecticide-treated nets and repellents, soon implemented
in the maternities of La Réunion, were not effective
against A. albopictus bites, a vector which was proven to
exercise a diurnal activity [6].
The slight difference between pregnant women and com-
munity may account for a selection phenomenon, the
pregnant women being not representative of the commu-
nity. However, the prevalence was higher in pregnancy
which argues against a significant selection bias, since
more than 50% of serum collections came from south and
west labs at a time when transmission was still predomi-
nant in theses micro-regions, leading to an unexpected
geographical adjustment on the transmission level.
The population-based survey provided a 38.2% preva-
lence rate in the post-epidemic era, i.e., about 300,000
people infected, by October 20, 2006 [7]. At the same
time, the CIRE data, published on the Institut national de
Veille Sanitaire website, estimated at 266,000 (34.3%) the
number of people infected [14]. Thus, the seroprevalence
in the community was slightly higher than the 34.3% esti-
mated for suspected cases (P < 0.001), but of the same
magnitude. This difference might correspond to unde-
clared cases to the CIRE, i.e., (1) the inapparent cases
(5.0%), although these would be compensated by an
approximately equal proportion of false positives (4.5%);
(2) patients who did not consult and performed auto-
medication; (3) patients who did not match the clinical
criteria for "suspected cases", i.e., sudden fever > 38.5 C°
and incapacitating arthralgia. Based on laboratory confir-
mations of atypical presentations, Renault et al. calculated
that approximately 3% of patients did not fulfil this defi-
nition [11]. Importantly, the SEROCHIK survey showed
that 25.8% of CHIKV-infected subjects did not declare
fever combined to arthralgia. This significant discrepancy
may result both from an information bias due to the struc-
ture of the questionnaire (subjects who were not aware of
their infection did not answer to questions about clinical
signs), or a memory bias due to the time interval between
the SEROCHIK survey and the onset of symptoms (2 to 15
months) that could preclude mild cases to remind their
symptoms. However, the declaration-based surveillance
system based on suspected cases may have also underesti-
mated the attack rate at the epidemic phase. The difference
was particularly notable from April to December 2005
(Figure 3), when the incidence was less than 500 new
cases per week (Figure 2) and the surveillance relied upon
active and retrospective case detection around the cases
declared. Ditto, it was verified from June 2006 (Figure 3),
when the incidence dropped dramatically shortly before
the epidemic stopped in August (Figure 2). It could be
explained by a lower PPV for each symptoms (< 85 to
92%) and for the clinical definition (< 87%), as the trans-
mission was low (Table 3). Indeed, it is well known that
when the incidence of a communicable disease is low, its
contribution to the clinical forms that can evoke it
decreases, with a consequent decline of the PPV for clini-
cal signs to identify the disease [22]. Moreover, the possi-
bility of concomitant circulation of other infections, such
as Influenza or Dengue [23], may have challenged the
diagnosis of Chikungunya [24], especially between April
and December 2005, or from June 2006.
Another important aspect of Chikungunya disease dis-
closed in the course of La Réunion outbreak is the low
proportion of inapparent forms (16%), in comparison
with those usually observed for other arbovirosis, such as
Dengue Fever (> 50%) [25,26] or West-Nile virus infec-
tion (> 70%) [27,28].
Finally, it is noteworthy that the 38.2% seroprevalence
rate observed in the post-epidemic phase [7] gives a valu-
able insight upon the herd immunity and a clearer picture
of susceptible people who could be infected in the future
(62.8%). Importantly, the seroprevalence observed in La
Réunion Island was far inferior to those reported recently
from the Kenyan island of Lamu (75%) [29] and the
Grande Comoro Island (63%) [30], two areas where
CHIKV emerged before to reach La Réunion [4,5].
Several hypotheses may explain this discrepancy in preva-
lence rates: 1°) Kenyan and Comorian climates are less
prone to seasonal variations and therefore more condu-
cive to a sustainable transmission; 2°) A. aegypti, the clas-
sical vector of Chikungunya, involved in Kenyan and
Comorian outbreaks, keeps a better capability to spread
the disease in domestic environment than the less anthro-
pophilic A. albopictus; 3°) for the same reason, the density
of susceptible hosts would be less important in perido-Page 7 of 9
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Comorian homes invaded by highly anthropophilic A.
aegypti; 4°) in La Réunion, floods brought by the cyclone
Diwa drove away larvae of A. albopictus from gullies and
hastened the decrease in transmission from early March
2006; 5°) effective vector control measures combining
eradication of breeding sites, adulticide and larvicide
treatments contributed to limit the density of vectors
throughout the Reunion outbreak; 6°) In La Réunion, the
herd immunity was gained more rapidly in the littoral
plains (where most of the population lives in contact with
vectors) which reduced transmission as the entry in the
dry austral winter. Indeed, some micro-geographical dif-
ferences in prevalence rates would have been not detected
by the SEROCHIK survey (whose sampling plan was
aimed at discriminating between micro-regions but not
within), and thereby prevalence rates in littoral plains
would have far exceeded the overall 38.2% rate, which
would have led to the premature decline of the epidemic
due to effective herd immunity.
Prevalence rates of 60 to 70% were necessary to delay
resurgences to 20 to 30 years in areas where CHIKV had
circulated before [31]. According to a recent mathematical
model [32], it was concluded that in the best-fitting case
(reproductive number of 3.7), the attack rate would have
been of 73% which suggests that, with only 38.2% of peo-
ple infected, a re-emergence in La Réunion Island cannot
be excluded for the next years, as long as viral strains cir-
culate in the region. However, the scenario observed in La
Réunion seems thwart this mathematical prediction,
because so far, no case of Chikungunya has been scientif-
ically confirmed since August 2006. This could be
explained at municipality level by heterogeneity of repro-
ductive numbers that would have been very sensitive to
local interventions in vector control [33].
Conclusion
Congruent estimates of Chikungunya attack rate were
observed at the upsurge of La Réunion Island outbreak,
either using clinical declaration of suspected cases
(16.5%), or a rapid serosurvey in pregnant women
(18.2%). In contrast, a discrepancy was observed in the
post-epidemic era, when clinical diagnosis underesti-
mated the attack rate (34.3%) in comparison to seroprev-
alence estimate (38.2%; 95% CI, 35.9 to 40.6%). Thus, a
rapid serosurvey in a targeted population can be helpful to
assess the extent of epidemics at time of emergency when
large seroprevalence studies cannot be done. Beyond this
indication, our findings suggest that prospective real time
surveillance of attack rates in pregnant women would
serve as a good model for population monitoring in the
event of Chikungunya outbreaks. However, although it
may fail to detect micro-geographical differences in prev-
alence rates at municipality level, a population-based
serosurvey can still be useful to refine the clinical esti-
mates and to assess more precisely the herd immunity.
Moreover, only a representative survey can bring an over-
view on risk factors and other conditions facilitating the
transmission. Finally, this work speaks to the usefulness
of serosurveys for the quantification of epidemics, as to
cost-containment in public health. It also provides valua-
bles clues for monitoring epidemics in high and low-
incomes countries.
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